Nicola Deidre Petal Greenway insider trades: Takeda Pharmaceutical (TAK) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nicola reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | TAK | ↓ Sell | 12,980 | $18.11 | $235K | Direct | Aug 19, 2026 (1d) |
| Aug 10, 2026 | TAK | ↓ Sell | 34,603 | $17.51 | $606K | Direct | Aug 12, 2026 (2d) |
| Aug 10, 2026 | TAK | ↓ Sell | 6,774 | $17.10 | $116K | Direct | Aug 12, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TAK insiders
Open-market trades in the last 12 months
About Nicola Deidre Petal Greenway's insider trades
Nicola Deidre Petal Greenway is Chief Human Resources Officer at Takeda Pharmaceutical (TAK). Since Aug 10, 2026, Nicola has reported no open-market purchases and 3 sales worth $957K on SEC Form 4. In the last 12 months: 3 sales ($957K).
Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TAK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.